Amarin Corp Plcuk
AMRN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000897448
No open-market purchases or sales by Amarin Corp Plcuk insiders were filed in the last 90 days; 81 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 29, 2026, 1:12 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $38.8M (18.2% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Mar 12, 2025 | Jan 10, 2024 | Jan 10, 2023 | Jan 10, 2022 |
| Revenue | $213.6M | $228.6M | $306.9M | $369.2M | $583.2M |
| Cost of revenue | – | – | – | – | $121.3M |
| Gross profit | $120.9M | $81.4M | $165.5M | $242.5M | $461.9M |
| Operating expenses | $171.0M | $173.2M | $233.1M | $348.4M | $451.4M |
| Research and development | $19.8M | $20.9M | $22.2M | $30.4M | $29.3M |
| Selling, general and administrative | $115.0M | $152.3M | $199.9M | $304.4M | $408.3M |
| Operating income | -$50.2M | -$91.8M | -$67.6M | -$105.9M | $10.5M |
| Interest expense | $7.00K | $7.00K | $8.00K | $15.0K | $129.0K |
| Income tax | $2.75M | $4.98M | $5.44M | $2.00M | $3.56M |
| Net income | -$38.8M | -$82.2M | -$59.1M | -$105.8M | $7.73M |
| EPS, basic | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 |
| EPS, diluted | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 |
| Weighted shares, basic | 415.0M | 410.9M | 407.7M | 401.2M | 396.0M |
| Weighted shares, diluted | 415.0M | 410.9M | 407.7M | 401.2M | 402.5M |
| Margins and growth | |||||
| Gross margin | 56.6% | 35.6% | 53.9% | 65.7% | 79.2% |
| Operating margin | -23.5% | -40.2% | -22.0% | -28.7% | 1.8% |
| Net margin | -18.2% | -35.9% | -19.3% | -28.7% | 1.3% |
| Revenue growth, year over year | −6.5% | −25.5% | −16.9% | −36.7% | −5.0% |
| Net income growth, year over year | – | – | – | −1,468.9% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Mar 12, 2025 | Jan 10, 2024 | Jan 10, 2023 | Jan 10, 2022 |
| Cash and equivalents | $134.7M | $121.0M | $199.3M | $217.7M | $219.5M |
| Short-term investments | $167.9M | $173.2M | $121.4M | $91.7M | $234.7M |
| Accounts receivable | $126.8M | $122.3M | $133.6M | $131.0M | $163.7M |
| Inventory | $195.9M | $166.0M | $258.6M | $228.7M | $234.7M |
| Total current assets | $649.9M | $595.4M | $725.0M | $689.1M | $878.7M |
| Property, plant and equipment | $12.0K | $16.0K | $114.0K | $874.0K | $1.43M |
| Intangible assets | $13.4M | $16.4M | $19.3M | $21.8M | $23.5M |
| Total assets | $670.8M | $685.3M | $831.7M | $886.2M | $1.07B |
| Accounts payable | $45.4M | $40.4M | $52.8M | $64.6M | $114.9M |
| Short-term debt | – | – | – | – | $0 |
| Total current liabilities | $194.5M | $179.9M | $259.3M | $259.5M | $370.7M |
| Total liabilities | $211.5M | $199.2M | $279.6M | $290.8M | $401.0M |
| Shareholders' equity | $459.3M | $486.2M | $552.1M | $595.3M | $667.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Mar 12, 2025 | Jan 10, 2024 | Jan 10, 2023 | Jan 10, 2022 |
| Operating cash flow | $6.73M | -$31.0M | $6.88M | -$180.1M | -$66.5M |
| Stock-based compensation | $13.9M | $17.7M | $15.6M | $26.2M | $36.9M |
| Investing cash flow | $8.83M | -$46.0M | -$25.5M | $175.3M | $104.1M |
| Financing cash flow | -$2.03M | -$1.44M | $230.0K | -$379.0K | -$5.07M |
| Net change in cash | $13.5M | -$78.4M | -$18.4M | -$5.18M | $32.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 6.5% | 7.7% | 5.1% | 7.1% | 6.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-20 in Q2 2025.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.